Cargando…
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
On the basis of preclinical data suggesting the possibility of maximising the efficacy of 5-fluorouracil and cisplatin by interferon, a pilot clinical trial was initiated in recurrent and/or metastatic head and neck cancer. Thirty-four patients were treated with cisplatin at 100 mg m-2, followed by...
Autores principales: | Cascinu, S., Fedeli, A., Luzi Fedeli, S., Catalano, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968704/ https://www.ncbi.nlm.nih.gov/pubmed/8297740 |
Ejemplares similares
-
Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
por: Cascinu, S., et al.
Publicado: (1993) -
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin
por: Hsieh, Chen-Hsi, et al.
Publicado: (2013) -
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
por: Vermorken, J B, et al.
Publicado: (2011) -
Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014) -
Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hsieh, Meng-Che, et al.
Publicado: (2021)